Contemporary Status and Frontiers of Cervical Cancer Screening in the United States
Authors:
- Abbigael V. EliAEAbbigael V. Eli
- Benjamin B. KastenBKBenjamin B. Kasten
- Christopher M. MayerCMChristopher M. Mayer
- Rishab SamantRSRishab Samant
- Yolanda E. HartmanYHYolanda E. Hartman
- Isha ChaudharyICIsha Chaudhary
- Noorullah ImranNINoorullah Imran
- Valeria L. Dal ZottoVZValeria L. Dal Zotto
- Andrea G. KahnAKAndrea G. Kahn
- Rebecca C. ArendRARebecca C. Arend
- Jason M. WarramJWJason M. Warram
Open Access
- 29 August 2025
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 18 (11) , 663-675
Abstract
Cervical cancer screening and its implementation have evolved tremendously since the first method, cytology using the Papanicolaou stain, was introduced in the 1950s. New screening methods, such as human papillomavirus testing, have been discovered, and evidence-based changes have been made to official screening guidelines set forth by various US organizations. With the advent of a human papillomavirus vaccine in 2006 and with more recent research into populations carrying disparate burdens of cervical disease, the effectiveness of current cervical cancer screening programs is being called into question as the disease incidence has not decreased as expected in the past 20 years. This review highlights where cervical cancer screening in the United States started, the current clinical methods, and promising developments on the frontiers of screening research to introduce new screening options or improve current screening programs and outcomes. We also highlight certain population factors that hinder effective screening in high-risk groups, based on research aimed at ensuring that population-wide screening continues to be an effective strategy for reducing cervical cancer incidence and mortality.Keywords
This publication has 90 references indexed in Scilit:
- Cervical Cancer Screening Rates Among Rural and Urban Females, From 2019 to 2022JAMA Network Open, 2024
- Assessment of US Preventive Services Task Force Guideline–Concordant Cervical Cancer Screening Rates and Reasons for Underscreening by Age, Race and Ethnicity, Sexual Orientation, Rurality, and Insurance, 2005 to 2019JAMA Network Open, 2022
- Cervical cancer: Automation of Pap test screeningDiagnostic Cytopathology, 2021
- Screening for Cervical CancerJAMA, 2018
- Screening for Cervical Cancer With High-Risk Human Papillomavirus TestingJAMA, 2018
- The clinical impact of using p16INK4a immunochemistry in cervical histopathology and cytology: An update of recent developmentsInternational Journal of Cancer, 2014
- Ohio Appalachian women's perceptions of the cost of cervical cancer screeningCancer, 2010
- Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopyInternational Journal of Cancer, 2000
- HPV DNA Testing of Self-collected Vaginal Samples Compared With Cytologic Screening to Detect Cervical CancerJAMA, 2000
- Human papillomavirus is a necessary cause of invasive cervical cancer worldwideThe Journal of Pathology, 1999